Gut Microbiome’s Role in Psoriasis and Arthritis Therapies

The Gut-Skin-Immune Axis: A Potential Target for Psoriasis

Researchers from the Medical College of Wisconsin and UCSF identified significant gut microbiome differences in people with psoriasis and psoriatic arthritis. Their scoping review, which synthesized 30 studies involving over 749,000 participants, found 18 studies reporting distinct microbial profiles compared to healthy individuals. This connection suggests the gut microbiome is a legitimate target for therapies aiming to modulate the systemic inflammation that drives these skin and joint conditions.

The Firmicutes/Bacteroidetes Ratio and SCFA Production

One specific microbial signature drew attention from Kent, Chao, Liao, and Singla’s team: the Firmicutes to Bacteroidetes (F/B) ratio. Findings were mixed, with one study indicating a low ratio and five others suggesting an elevated ratio in psoriasis patients. The ratio’s importance may lie in its functional output. A higher F/B ratio correlated with increased production of acetate, a key short-chain fatty acid (SCFA). Alongside propionate, these SCFAs are not just metabolic byproducts. They act as signaling molecules that can modulate the IL-23/Th17 immune axis, a pathway directly responsible for activating keratinocytes and fueling the psoriatic inflammatory cycle. This provides a direct mechanistic link between gut bacteria composition and skin inflammation.

Mixed Outcomes for Microbiome-Directed Therapies

The review explored how different interventions affect this system. Conventional immune-modulating drugs themselves have microbiome effects. Ustekinumab (which targets IL-12/23) and tofacitinib (a JAK inhibitor) were noted to alter gut microbiome composition, though the clinical meaning of these changes requires more study. For direct microbiome therapies, results varied. Six out of eight probiotic studies reported favorable shifts, such as increases in SCFA-producing species and reductions in inflammatory markers. The data for fecal microbiota transplantation (FMT), however, revealed a stark contrast between animal models and human experience. FMT improved immune markers in mice, but human trials showed no significant clinical benefit for psoriatic disease, underscoring the challenges of translating microbiome research into effective human treatments.

FMT’s Established Role and Expanding Pediatric Applications

Fecal microbiota transplantation has one clearly proven application: treating recurrent Clostridioides difficile infection (rCDI). The success here, based on restoring colonization resistance, has propelled research into other areas of dysbiosis. A separate 2026 review by Zambelli and colleagues at the University of Parma examined FMT’s role in pediatric disorders. Given the gut microbiome’s central role in early-life immune maturation and metabolic health, restoring microbial balance is a logical strategy for childhood conditions linked to dysbiosis. This work reinforces the concept of FMT as a powerful tool for microbial restoration, even as its applications beyond rCDI remain under rigorous investigation. For managing complex, multifactorial conditions like IBS-C, which involves motility, sensitivity, and microbiome factors, FMT research contributes to a broader understanding of microbial therapeutics.

Practical Implications and Cautious Optimism

For individuals with gut-health concerns, IBS, or SIBO, this research clarifies the current state of evidence. The strong association between gut dysbiosis and systemic inflammatory disease is undeniable, providing a scientific basis for dietary and probiotic approaches that support a healthier microbiome. For instance, consuming fermented foods or specific fibers can boost SCFA production, a beneficial effect highlighted in the psoriasis research. However, the human trial data for FMT in inflammatory conditions is a sobering counterpoint to animal study enthusiasm and media hype. It suggests that simply transferring a complete microbiome may not be sufficient to overcome entrenched immune dysfunction in diseases like psoriasis. A more nuanced, personalized approach that may combine dietary support, targeted probiotics, and conventional treatment—similar to the pathophysiology-driven treatment advocated for IBS-C—is where the most immediate promise lies.

Conclusion

Evidence solidly links a disrupted gut microbiome to inflammatory conditions like psoriasis, with SCFAs serving as key communicators along the gut-skin axis. While FMT successfully treats rCDI, its utility for complex inflammatory diseases remains unproven in humans, highlighting the gap between mechanistic understanding and clinical therapy. Current practical strategies should focus on supporting a beneficial microbiome through diet and probiotics, informed by ongoing research.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42358596/
https://pubmed.ncbi.nlm.nih.gov/42354867/